Companies Cryptocurrencies
Denali Therapeutics Inc
Denali Therapeutics Inc
Exchange: Nasdaq Global Select
IPO Date: 08/12/2017
CEO: Mr. Ryan Watts
Biotechnology Healthcare 🔗
  • DNLI
  • 29.43
  • 3618359552
    market cap
  • 0.45000076
If you bought

shares of Denali Therapeutics Inc (DNLI) on
You would have made
Old Price $12 Current Price $12

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 255 full-time employees. The firm is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and others. The firm is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease. The firm has selected approximately four specific pathways that are implicated as triggers or effectors of neurodegeneration, including degenogenes (genes that cause neurodegenerative disease when mutated), defective intracellular trafficking, glial dysfunction and axon degeneration. The Company’s development programs include Lysosomal Function Pathway, Glial Biology Pathway, and Cellular Homeostasis Pathway. Its product pipeline includes drug candidates such as DNL201, DNL 151, ATV:aSyn, ETV:IDS, DNL747, and ATV:TREM2.

Address: 161 Oyster Point Blvd South San Francisco CALIFORNIA 94080

Stay updated.